| Drug / Therapy | zanzalintinib |
| Indication | renal cell carcinoma |
| Decision Type | PDUFA |
| Conditions | renal cell carcinoma |
| Interventions | zanzalintinib |
Exelixis Inc (EXEL) operates in the Oncology sector. The current BTS Score is 55 (Grade: C).
Biotech companies frequently raise capital through secondary offerings, ATM programs, and convertible notes. Before or after major FDA decisions, dilution events are common. Understanding a company's dilution history is critical for managing risk around catalyst dates.
The PDUFA date for zanzalintinib by Exelixis Inc (EXEL) is scheduled for July 20, 2026. This is the target date for the FDA to make a decision on this application.
zanzalintinib is being developed by Exelixis Inc for the treatment of renal cell carcinoma. It is under FDA review.
If zanzalintinib receives FDA approval, Exelixis Inc (EXEL) would be able to market the drug in the United States for renal cell carcinoma. This typically leads to significant stock price movement for biotech companies. Investors should monitor the PDUFA date closely.
Biotech companies often raise capital through share offerings, which can dilute existing shareholders. You can check the current dilution risk for EXEL on DilutionWatch at dilutionwatch.com/stock/EXEL.html.
You can view the full BiotechSigns company profile for Exelixis Inc (EXEL) at biotechsign.com/app/company/EXEL, which includes the BTS Score, signal history, clinical trial data, and insider trading activity.
This page is for informational purposes only and does not constitute investment advice. FDA decision dates are subject to change. Clinical trial outcomes are inherently uncertain. Biotech stocks are highly volatile — past performance does not guarantee future results. Always consult a qualified financial advisor before making investment decisions. BiotechSigns is not a registered investment advisor.